Daraxonrasib
Daraxonrasib (RMC-6236) is a first-in-class non-covalent KRAS(ON) inhibitor that forms a tri-complex with cyclophilin A (CYPA) as a molecular glue, selectively inhibiting the active (GTP-bound) form of RAS across multiple oncogenic variants including KRAS G12D, G12V, G12C, G13D, and wild-type KRAS in RAS-amplified settings. Phase III trials (RASolve) in PDAC and NSCLC are actively enrolling.
Description
Scientific Overview: Daraxonrasib (RMC-6236) is a first-in-class non-covalent KRAS(ON) inhibitor that forms a tri-complex with cyclophilin A (CYPA) as a molecular glue, selectively inhibiting the active (GTP-bound) form of RAS across multiple oncogenic variants including KRAS G12D, G12V, G12C, G13D, and wild-type KRAS in RAS-amplified settings. Phase III trials (RASolve) in PDAC and NSCLC are actively enrolling.
Mechanism of Action: Pan-RAS(ON) Multi-Selective Inhibitor (non-covalent tri-complex)
Purity: ≥99% | Molecular Formula: C44H58N8O5S
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | Pan-RAS(ON) Multi-Selective Inhibitor (non-covalent tri-complex) |
|---|---|
| Purity | ≥99% |
| Molecular Formula | C44H58N8O5S |
| CAS Number | 2765081-21-6 |
